B&K Corp. Ltd. engages in the research, development, discovery and commercialization of systematic and integrated biomacromolecule therapeutic drugs for a multiple diseases, including thermal burns, DFUs, pressure ulcers, hemorrhoids, photodermatitis, radiation ulcers, fresh wounds, gastric ulcers, dry eye syndrome, corneal injury, and alopecia. Its core products are Pro-101-1 and Pro-101-2 which are PDGF candidates for the treatment of thermal burns and DFUs. The company also offers medical devices and cosmetics products. B&K was founded by Jia Li Jia on April 24, 2012 and is headquartered in Qingdao, China.